Categories: News

Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Live video webcast presentation on Friday, February 18th at 10:40 AM ET

ISELIN, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 10:40 AM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the Events page of the Investors section of Outlook Therapeutics’ website (outlooktherapeutics.com). A webcast replay will be available following the live presentation and will be accessible for 90 days.

About Outlook Therapeutics, Inc.        

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:       
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com 

Staff

Recent Posts

NextStep Arthropedix to Launch TheRay™ Hip System

NextStep Arthropedix, a growing orthopedics company, announces the launch of TheRay™ Collared and Collarless Hip System.…

6 hours ago

SPS Health Acquires Mideast Delivery Solutions to Enhance Healthcare Delivery Network

MILWAUKEE, WI / ACCESSWIRE / July 15, 2024 / SPS Health, a leading innovator in…

6 hours ago

Avant Brands Reports Continued Growth in Q2 2024 Financial Results

Record Gross Revenue: Generated $9.4 million in gross revenue, establishing a new company record.Strong International…

6 hours ago

NHI Announces Second Quarter 2024 Earnings Release and Conference Call Date

MURFREESBORO, TN / ACCESSWIRE / July 15, 2024 / National Health Investors, Inc. (NYSE:NHI) announced…

6 hours ago

B2B Pharmacy Services Now Available from Canada Pharmacy

Established Canadian online pharmacy now partnering with smaller pharmaciesVICTORIA, BC / ACCESSWIRE / July 15,…

6 hours ago